| 1. |
Heuyer G, Gerard G, Galibert J. Traitement de
I'excitation psychomotrice chez I'enfant. Arch Fr Pediatr 1953;9:961. |
| 2. |
Miksztal MW. Chlorpromazine (thorazine) and reserpine in
residential treatment of neuropsychiatric disorders in children. J Nerv
Ment Dis 1956;123:477-9. |
| 3. |
Tarjan L, Lowery VE, Wright SW. Use of clorpromazine in 278
mentally defecient patients. AMA J Disturbed Child 1957:94:294-300. |
| 4. |
Werry JS, Weiss G, Douglas V, Martin J. Studies on the hiperactive
child, III: The effect of chlorpromazine upon behavior and learning
ability. J Am Acad Child Psychiatry 1966;5:292-312. |
| 5. |
Cunningham MA, Pillai V, Blachford-Rogers WJ. Haloperidol in the
treatment of children with severe behavior disorders. Br J Psychiatry
1968;114:845-54. |
| 6. |
Morselli PL, Cuche H, Zarifian E. Pharmacokinetics of psychotropic
drugs in the pediatric patient. En: Mendelewicz J, Van Praag HM,
editores. Childhood psychopharmacology: current concepts. Basilea: S.
Karges; 1978. |
| 7. |
Campbell M. Schizophrenic disorders and pervasive developmental
disorders/infantile autism. En: Wiener JM, editor. Diagnosis and
psychopharmacology of childhood and adolescent disorders. New York: John
Wiley & Sons; 1985. |
| 8. |
Wolpert A, Hagamen MB, Merlis S. A comparative study of thiothixene
and trifluoperazine in childhood schizophrenia. Curr Ther Res
1967;9:482-5. |
| 9. |
Campbell M, Anderson LT, Meier M, Cohen IL, Small AM, Samit C, et
al. A comparison of haloperidol, behavior therapy and their interaction
in autistic children. J Am Acad Child Psychiatry 1978;17:640-55. |
| 10. |
Anderson LT, Campbell M, Grega DM, Perry R, Small AM, Green WH.
Haloperidol in infantile autism: Effects on learning and behavioral
symptoms. Am J Psychiatry 1984;141:1195-201. |
| 11. |
Campbell M, Small AM, Green WH, Jennings SJ, Perry R, Bennett WG,
et al. Behavioral efficacy of haloperidol and lithium carbonate: A
comparison in hospitalized aggressive children with conduct disorder.
Arch Gen Psychiatry 1984;4:650-6. |
| 12. |
Klein SK, Levinsohn MW, Blumer JL. Accidental chlorpromazine
ingestion as a cause of neuroleptic malignant syndrome in children. J
Pediatr 1985;107:970-3. |
| 13. |
Campbell M, Green WH, Deutsch SL. Child and adolescent
Psychopharmacoloy. Beverly Hills: Sage Publications; 1985. |
| 14. |
Mikkelsen EJ, Detlor J, Cohen DJ. School avoidance and social
phobia triggered by haloperidol in patients with Tourette's disorder. Am
J Psychiatry 1981;138:1139-44. |
| 15. |
Gallhofer B, Bauer U, Lis S, Krieger S, Gruppe H. Cognitive
dysfunction in schizophrenia: comparison of treatment with atypical
antipsychotic agents and conventional neuroleptic drugs. Eur
Neuropsychopharmacol 1996;6:13-20. |
| 16. |
Baldessarini RJ. Clinical and epidemiologic aspects of tardive
dyskinesia. J Clin Psychiatry 1985;46:8-13. |
| 17. |
Perry R, Campbell M, Green WH, Small AM, Die Trill ML, Meiselas K,
et al. Neuroleptic-related dyskinesias in autistic children: A
prospective study. Psychopharmacol Bull 1985;21:140-3. |
| 18. |
Gualtieri CT, Quade D, Hicks RE, Mayo JP, Schroeder SR. Tardive
dyskinesia and other clinical consequences of neuroleptic treatment in
children and adolescents. Am J Psychiatry 1984;141:20-3. |
| 19. |
Richardson MA, Howland G, Graig TJ. Neuroleptic use, parkinsonian
symptoms, tardive dyskinesia and associated factors in child and
adolescent psychiatric patients. Am J Psychiatry 1991;148:1322-8. |
| 20. |
American Psychiatric Association. Tardive Dyskinesia: a task force
report of the American Psychiatric Association. En: Kane JM, Jeste DV,
Barnes TRE, et al., editores. Washington: American Psychiatric
Association; 1992. |
| 21. |
Muscettola G, Pampallona S, Barbato G, Casiello M, Bollini P.
Persistent tardive dyskinesia: demographic and pharmacological risk
factors. Acta Psychiatr Scand 1993;87:29-36. |
| 22. |
Lipman RS, DiMascio A, Reating N, Kirson T. Psychotropic drugs and
mentally retarded children. En: Lipton MA, DiMascio A, Killam KF,
editores. Psychopharmacology: a generation of progress. New York: Raven
ress; 1978. |
| 23. |
Baldessarini RJ. Chemotherapy in Psychiatry. Cambridge, Ma: Harvard
University Press; 1977. |
| 24. |
Simeon J, Gress M, Mueller J. Neuroleptic drug effects on
children's body weight and height. Psychopharmacol Bull 1977;13:50-3. |
| 25. |
Meltzer HY, Rabinowitz J, Lee MA, Cola PA, Ranjan R, Findling RL,
et al. Age at onset and gender of schizophrenic patients in relation to
neuroleptic resistance. Am J Psychiatry 1997;154:475-82. |
| 26. |
American Psychiatric Association. Manual diagnóstico y estadístico
de los trastornos mentales. DSM-IV. Barcelona: Masson; 1997. |
| 27. |
Pickar D, Owen RR, Litman RE, Konizki E, Gutiérrez R,
Rapoport MH. Clinical and biological response to clozapine in patients
with schizophrenia. Arch Gen Psychiatry 1992;49:345-53. |
| 28. |
Blanz B, Schmidt MH. Clozapine for schizophrenia [letter]. J Am
Acad Child Adolesc Psychiatry 1993;32:223-4. |
| 29. |
Frazier JA, Gordon CT, McKenna K, Lenane MC, Jih D, Rapoport JL. An
open trial of Clozapine in 11 adolescents with childhood-onset
schizophrenia. J Am Acad Child Adolesc Psychiatry 1994;33:658-63. |
| 30. |
Gordon CT, Frazier JA, McKenna K, Giedd J, Zametkin A, Zahn T, et
al. Childhood-onset schizophrenia: An NIMH study in progress. Schizophr
Bull 1994;20:697-712. |
| 31. |
Kumra S, Frazier JA, Jacobsen LK, McKenna K, Gordon CT, Lenane MC,
et al. Childhood-onset schizophrenia: a double-blind
clozapine-haloperidol comparison. Arch Gen Psychiatry 1996;53:1090-7. |
| 32. |
Turetz M, Mozes T, Toren P. An open trial of clozapine in
neuroleptic resistant childhood-onset schizophrenia. Br J Psychiatry
1997;170:507-10. |
| 33. |
Frazier JA, Giedd JN, Kaysen D, Albus K, Hamburger S, Alaghband-Rad
J, et al. Childhood-onset schizophrenia: brain MRI rescan after 2 years
of clozapine maintenance treatment. Am J Psychiatry 1996;153:564-6. |
| 34. |
Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan
GW, et al. A Canadian multicenter placebo-controlled study of fixed
doses of risperidone and haloperidol in the treatment of chronic
schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40. |
| 35. |
Marder SR, Meibach RC. Risperidone in the t reatment of
schizophrenia. Am J Psychiatry 1994;151:825-35. |
| 36. |
McCreadie RG. Managing the first episode of schizophrenia: the role
of new therapies. Eur Neuropsychopharmacol 1996;6 Supl 2:S3-S5. |
| 37. |
Kopala LC, Good KP, Honer WG. Extrapyramidal signs and clinical
symptoms in first-episode schizophrenia: response to low-dose
risperidone. J Clin Psychopharmacol 1997;17:308-13. |
| 38. |
Quintana H, Keshavan M. Risperidone in children and adolescents
with schizophrenia. J Am Acad Child Adolesc Psychiatry 1995;34:1292-6. |
| 39. |
Grcevich SJ, Findling RL, Rowane WA, Friedman L, Schulz SC.
Risperidone in the treatment of children and adolescents with
schizophrenia. A retrospective study. J Child Adolesc Psychopharmacol
1996;6:251-7. |
| 40. |
Armenteros JL, Whitaker AH, Welikson M, Stedge DJ, Gorman J.
Risperidone in adolescents with schizophrenia. An open pilot study. J Am
Acad Child Adolesc Psychiatry 1997;36:694-700. |
| 41. |
Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton
S. Olanzapine versus placebo and haloperidol: acute phase results of the
North American double-blind olanzapine trial. Neuropsychopharmacology
1996;14:111-23. |
| 42. |
Tollefson GD, Sanger TM. Negative symptoms: a path analytic
approach to a double-blind, placebo- and haloperidol-controlled clinical
trial with olanzapine. Am J Psychiatry 1997;154:466-74. |
| 43. |
Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C
Jr, et al. Double-blind comparison of olanzapine versus risperidone in
the treatment of schizophrenia and other psychotic disorders. J Clin
Psychopharmacol 1997;17:407-18. |
| 44. |
Kumra S, Jacobsen LK, Lename M, Karp BL, Frazier JA, Smith AK, et
al. Childhood-onset schizophrenia: An open label study of olanzapine in
adolescents. J Acad Child Adolesc Psychiatry 1998;37:377-85. |
| 45. |
Mandoki M. Society of Biological Psychiatry 52nd annual Convention
and scientific program. San Diego, California, May 14-18, 1997.
Abstracts. Biol Psychiatry 1997 Apr 1;41(7 Suppl):1S-128S. |
| 46. |
Zimbroff DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Wozniak PJ,
et al. Controlled, dose-response study of sertindole and haloperidol in
the treatment of schizophrenia. Sertindole Study Group. Am J Psiquiatry
1997;154:782-91. |
| 47. |
Tamminga CA, Mack RJ, Granneman GR, Silber CJ, Kashkin KB.
Sertindole in the treatment of psychosis in schizophrenia: efficacy adn
safety. Int J Psychopharmacol 1997;12 Supl 1:529-35. |
| 48. |
Bruun RD, Budman CL. Risperidone as a treatment for Tourette's
syndrome. J Clin Psychiatry 1996;57:29-31. |
| 49. |
Borison RL, Ang L, Chang S, et al. New pharmacological approaches
in the treatment of Tourette syndrome. En: Friedhoff AJ, Chase TN,
editores: Advances in Neurology (vol. 35) Gilles de la Tourette
Syndrome. New York: Raven Press; 1982. |
| 50. |
Kafantaris V. Treatment of bipolar disorder in children and
adolescents. J Am Acad Child Adolesc Psychiatry 1985;34:732-41. |
| 51. |
Keck PE Jr, Wilson DR, Strakowski SM, McElroy SL, Kizer DL,
Balistreri TM, et al. Clinical predictors of acute risperidone response
in schizophrenia, schizoaffective disorder, and psychotic mood
disorders, J Clin Psychiatry 1995;56:466-70. |
| 52. |
Ghaemi SN, Sachs GS, Baldassano CF, Truman CJ. Acute treatment of
bipolar disorder with adjunctive risperidone in outpatiens. Can J
Psychiatry 1997;42:196-9. |
| 53. |
Sajatovic M, DiGiovanni SK, Bastani B, Hattab H, Ramirez LF.
Risperidone therapy in treatment refractory acute bipolar and
schizoaffective mania. Psychopharmacol Bull 1996;32:55-61. |
| 54. |
Campbell M, Armenteros JL, Malone RP, Adams PB, Eisenberg ZW,
Overall JE. Neuroleptic-related dyskinesias in autistic children: a
prospective, longitudinal study. J Am Acad Child Adolesc Psychiatry
1997;36:835-43. |
| 55. |
McDougle CJ, Holmes JP, Bronson MR, Anderson GM, Volkmar FR, Price
LH, et al. Risperidone treatment of children and adolescents with
pervasive developmental disorders: a prospective open-label study. J Am
Acad Child Adolesc Psychiatry 1997;36:685-93. |
| 56. |
Zuddas A, Ledda MG, Fratta A, Muglia P, Cianchetti C. Clinical
effects of clozapine on autistic disorder. Am J Psichiatry 1996;153:5. |
| 57. |
Horrigan JP, Barnhill LJ, Courvoisie HE. Olanzapine in PDD. J Am
Acad Child Adolesc Psychiatry 1997;36:1166. |
| 58. |
Malek-Ahmadi P, Simonds JF. J Am Acad Child Adolesc Psychiatry
1998;37(9):902-3. |
| 59. |
Campbell M, Small AM, Green WH, et al. Lithium and haloperidol in
hospitalized aggressive children. Psychopharmacol Bull 1982;18:126-30. |
| 60. |
Sivam SP, Takeuchi K, Li S, Douglass J, Civelli O, Calvetta L,
Herbert E, et al. Lithium increases dynorphin A(1-8) and prodynorphin
mRNA levels in the basal ganglia of rats. Brain Res 1988;427:155-63. |
| 61. |
Ratey JJ, Leveroni C, Kilmer D, Gutheil C, Swartz B. The effects of
clozapine on severely aggressive psychiatric inpatients in a state
hospital. J Clin Psychiatry 1993;54:219-23. |
| 62. |
Rabinowitz J, Avnon M, Rosengerg V. Effect of clozapine on physical
and verbal aggression. Schizophr Res 1996;22:249-55. |
| 63. |
Cohen SA, Underwood MT. The use of clozapine in a mentally retarded
and aggressive population. J Clin Psychiatry 1994;55:440-4. |
| 64. |
Pregelj S, Barkauskas A. Thioridazine in the treatment of mentally
retarded children. A four year retroactive evaluation. J Can Psychiatr
Assoc 1967;12:213-5. |
| 65. |
Burk W, Menolascino F. Haloperidol in emotionally disturbed,
mentally retarded individuals. Am J Psychiatry 1968;124:1589-91. |
| 66. |
Le Vann L. Clinical comparison of haloperidol with clorpromazine in
mentally retarded children. American Journal of Mental Deficiency
1971;6:719-23. |
| 67. |
Breuning S, Ferguson D, Davidson N, Poling A. Effects of
thioridazine on the intellectual performance of mentally retarded drug
responders and nonresponders. Arch Gen Psychiatry 1983;40:309-13. |
| 68. |
Vanden Borre R, Vermote R, Buttiens M, Thiry P, Dierick G, Geutjens
J, et al. Risperidone as add-on therapy in behavioral disturbances in
mental retardation: a double-blind placebo controlled cross-over study.
Acta Psychiatr Scand 1993;87:167-71. |
| 69. |
Hardan A, Johnson K, Johnson C, Hrecznyj B. Case Study: Riperidone
treatment of children and adolescents with developmental disorders. J Am
Acad Child Adolesc Psychiatry 1996;35:1551-6. |
| 70. |
Rapoport J, Abramson A, Alexander D, Lott I. Playroom observations
of hyperactive children on medication. J Am Acad Child Psychiatr
1971;10:524-34. |
| 71. |
Weiss G, Minde K, Douglas V, Werry J, Sykes D. Comparison of the
effects of chlorpromazine, dextroamphetamine and methylphenidate on the
behavior and intellectual functioning of hiperactive children. Can Med
Assoc J 1971;104:20-5. |
| 72. |
Greenberg LM, Deem MA, McMahon S. Effects of dextroamphetamine,
chlorpromazine, hidroxyzine on behavior and performance in hyperactive
children. Am J Psychiatry 1972;129:532-9. |
| 73. |
Werry JS, Aman MG. Methylphenidate and haloperidol in children.
Arch Gen Psychiatry 1975;32:790-5. |
| 74. |
Gittelman-Klein R, Klein DF, Katz S, Saraf K, Pollack E.
Comparative effects of methylp henidate and thioridazine in hyperkinetic
children. I. Clinical results. Arch Gen Psychiatry 1976;33:1217-31. |
| 75. |
Teicher MH, Glod CA, Aaronson ST, Gunter PA, Schatzberg AF, Cole
JO. Open assessment of the safety and efficacy of thioridazine in the
treatment of patients with borderline personality disorder.
Psychopharmacol Bull 1989;25:535-49. |
| 76. |
Soloff PH, George A, Nathan RS, et al. Amitriptyline versus
haloperidol in borderlines: final outcomes and predictors of response. J
Clin Psychopharmacol 1989;9:238-46. |
| 77. |
Goldberg SC, Schulz SC, Schulz PM, Resnick RJ, Hamer RM, Friedel
RO. Borderline and schizotypal personality disorders treated with
low-dose thiothixene versus placebo. Arch Gen Psychiatry 1986;43:680-6. |
| 78. |
Cowdry RW, Gardner DL. Pharmacotherapy of borderline personality
disorder: alprazolam, carbamazepine, trifluoperazine and
tranylcypromine. Arch Gen Psychiatry 1988;45:111-9. |
| 79. |
Montgomery SA, Montgomery D. Pharmacological prevention of suicidal
behavior. J Affect Disord 1982;4:219-98. |
| 80. |
Kaplan HI, Sadock BJ, Grebb JA. Sinopsis de psiquiatría. 7ª
ed. Madrid: Médica Panamericana; 1996. |
| 81. |
Gordo R, García JA, de la Gándara JJ. Eficacia de
olanzapina en el trastorno límite de personalidad asociado a
T.C.A.. En: VIII Congreso Nacional de Psiquiatría
infanto-juvenil. 25-27 Junio 1998; Barcelona. Abstract en Rev Psiquiatr
Infant Juv 1998 Jun:62. |
| 82. |
Chinchilla A, Calvo R, Rodríguez B, Zamarrón I.
Anorexia y Bulimia Nerviosa. Madrid: Ergon; 1994. |
| 83. |
Fisman S, Steele M, Short J, Byrne T, Lavallee C. Case study:
anorexia nervosa and autistic disorder in an adolescent girl. J Am Acad
Child Adolesc Psychiatry 1996;35(7):937-40. |
| 84. |
Vivanco N, Pumarino H. Tratamiento de la anorexia nerviosa. Rev Med
Chil 1992;120(1):69-75. |
| 85. |
García JA, Gordo R, de la Gándara JJ. Eficacia de
Olanzapina en los trastornos de la conducta alimentaria. En: III
Congreso Nacional de Psiquiatría Biológica. 20-24 Octubre
1998; Platja d'Aro, Girona. Abstract en Actas Luso Esp Neurol Psiquiatr
Cienc Afines 1998;26:153. |
| 86. |
Toro J, Castro J, García M, Lázaro L. Psicofarmacología
clínica de la infancia y la adolescencia. Barcelona: Masson;
1998. |